TTUHSC School of Medicine Cancer Center
Home School of Medicine Cancer Center

Recent Publications

2009

  1. MH Kang, N Harutyunyan, CP Hall, RA Papa, RB Lock. (2009). In vitro and in vivo Activity of Methotrexate and Aminopterin against acute lymphoblastic leukemia and lymphoma. Br. J. Haematol. 145, 389-393.

2010

  1. Smith MA, Morton CL,: Kolb, EA, Gorlick, R, Keir ST, Carol H, Lock RB, Kang MH, Reynolds CP, MD, Maris JM, Watkins AE, Houghton PJ: Initial testing (Stage 1) of mapatumumab (HGS-ETR1) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 54:307-10, 2010.
  2. Houghton PJ, Morton CL, Gorlick R, Lock RB, Carol H, Reynolds CP, Kang MH, Maris JM, Keir ST, Kolb EA, Wu J, Wozniak AW, Billups CA, Rubinstein L, Smith MA: Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program. Mol Cancer Therapeutics 9:101-12, 2010.
  3. Hazen RA, Eder M, Ph.D., Drotar D, Zyzanski S, Reynolds AE, M.F.A, Reynolds CP, Kodish E, Noll RB: A feasibility trial of a video intervention to improve informed consent for parents of children with leukemia Pediatr Blood Cancer 55:113-8, 2010.
  4. Horton TM, Sposto R, Brown P, Reynolds CP, Hunger SP, Winick N, Raetz E, William Carroll W, Arceci A, Borowitz M, Gaynon P, Gore L, Jeha S, Maurer B, Siegel SE, Biondi A, Kearns P, Narendran A, Silverman L, Smith M, Zwaan M, Whitlock J: Toxicity assessment of new agents incorporated into induction regimens for pediatric acute lymphocytic leukemia (ALL): Results of an international consensus conference. Pediatr Blood Cancer 54:872-878, 2010.
  5. Kang HG, Jenabi JM, Liu XF, Reynolds CP, Triche TJ, Sorensen PH: Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Therapeutics 9:1396-407, 2010.
  6. Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ: Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 55:26-34, 2010.
  7. Houghton PJ, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wu J, Smith MA: Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatr Blood Cancer 54:921-6, 2010.
  8. Lee J, Singh H, Maurer BJ, Reynolds CP, Kang MH: A validated LC with fluorescence detection method for simultaneous determination of safingol and D-erythro-sphinganine in human plasma. Chromatographia 71:1087-1091 2010.
  9. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA: Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:295-303, 2010.
  10. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of AZD6244 (ARRY-142886) by the pediatric preclinical testing program. Pediatr Blood Cancer. 55:668-77,2010.
  11. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK, Shimada H, Grupp SA, Seeger RC, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM: Anti-GD2 antibody with GM-CSF, IL2 and isotretinoin for neuroblastoma: A Children's Oncology Group (COG) Phase III Study. New England J Medicine 363:22-32, 2010.
  12. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, Stram D, Castleberry RP, Shimada S, Sandler A, Shamberger RC, Look AT, Reynolds CP, Seeger RC, Matthay KK: Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England J Medicine 363:1313-1323, 2010.
  13. Houghton PJ, Morton CL, Kang MH, Reynolds CP, Billups CA, Favours E, Payne-Turner D, Tucker C, Smith MA: Evaluation of cytarabine against Ewing sarcoma xenografts by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 55:1224-6, 2010.
  14. Shusterman SS, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MRA, Wagner B, Gan J, Eickhoff J, De Santes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, and Sondel PM: Anti-tumor activity of hu14.18-IL2 (EMD 273063) in relapsed/refractory neuroblastoma patients: a Children's Oncology Group (COG) phase II study. J Clinical Oncology 28:4969-75, 2010.
  15. Cai, W, Maldonado V, Ji L, Sposto R, Reynolds CP, Keshelava N: Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer 103:1369-1379, 2010.
  16. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, Morton CL, Reynolds CP, Kang MH, Watkins A, Houghton PJ, Smith MA: Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1126-33, 2010.
  17. Hadjidaniel MD and Reynolds CP: Antagonism of cytotoxic chemotherapy in neuroblastoma cell lines by retinoic acid is mediated by the anti-apoptotic Bcl-2 family proteins. Mol Cancer Therapeutics 9:3164-74, 2010.
  18. Kapranov P, St. Laurent G, Raz T, Fatih Ozsolak F, Reynolds CP, Sorensen PHB, Reaman G, Milos P, Arceci RJ, Thompson JF, Triche TJ: The majority of total nuclear-encoded non-ribosomal RNA in a human cell is "dark matter" unannotated RNA BMC Biology 8:149 [Epub] 2010
  19. Carol H, Morton CL, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ, Lock RB: Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program. Pediatr Blood Cancer 55:1329-37, 2010.
  20. Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA: Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program Pediatr Blood Cancer. 2010 Dec 27. [Epub]

2011

  1. JP Cooper, S Bang, H Singh, SC Williams, MH Kang. (2011) Fenretinide cytotoxicity is independent of both constitutive and pharmacologically modulated glutathione levels in pediatric acute lymphoblastic leukemia cells cultured at hypoxia. Pediatric Blood Cancer. (in press).
  2. C Zhang, YK Ryu, TZ Chen, CP Hall, DR Webster, MH Kang. (2011) Synergistic Activity of Rapamycin and Dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis. Leukemia Res. (in press).
  3. Kang MH, Smith MA, Morton CL, Nino Keshelava N, Houghton PJ, Reynolds CP: National Cancer Institute Pediatric Preclinical Testing Program: Model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 56:239-49, 2011.
  4. Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Phelps D, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program. Pediatr Blood Cancer 58:191-9, 2011
  5. Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ: Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer. 56:595-603, 2010
  6. Smith MA, Maris JM, Lock R, Kolb EA, Gorlick R, Keir ST, Carol H, Morton CL, Reynolds CP, Kang MH, Houghton PJ: Initial Testing (Stage 1) of the polyamine analog PG11047 by the Pediatric Preclinical Testing Program Pediatr Blood Cancer 57:268-74, 2011.
  7. Reynolds CP, Kang MH, Keir ST, Gorlick R, Kolb EA, Lock R, Maris JM, Carol H, Morton CL, Billups CA, MS, Smith MA, MD, Houghton PJ: Initial testing of lenalidomide by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 57:606-11, 2011.
  8. Cooper J, Kyunghwa H, Hardeep S, Wang, D, Reynolds CP, Robert C, Simon W, Maurer BJ, Kang MH: Fenretinide metabolism in humans and mice: Utilizing pharmacologic modulation of its metabolic pathway to increase systemic exposure. British J Pharmacology 163:1263-75, 2011.
  9. Carol H, Boehm I, Reynolds CP, Kang MH, Maris JM, Morton CL, Gorlick R, Kolb EA, Keir ST, Wu J, Wozniak AE, Yang Y, Manfredi M, Ecsedy J, Wang J, Neale G, Houghton PJ, Smith MA, Lock RB: Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer. Cancer Chemother Pharmacol. 68:1291-304, 2011
  10. Kummar S, Gutierrez ME, Maurer BJ, Reynolds CP, Kang M, Singh H, Crandon S, Murgo AJ, Doroshow JH: Phase I trial of fenretinide Lym-X-sorb oral powder in adults with solid tumors and lymphomas. Anticancer Res. 31:961-6, 2011.
  11. Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP: Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clinical Cancer Research 17:7093-104, 2011.
  12. Villablanca JG, London WB, Naranjo A, McGrady MS, Ames MM, Joel M. Reid JM, McGovern RM, Buhrow SA, Stranzinger JH, Kitchen BJ, Sondel PM, Parisi M, Shulkin B, Yanik GA, Cohn S, Reynolds CP: Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group NSC #374551; IND# 40294. Clinical Cancer Research 17:6858-6866, 2011.

2012

  1. Kang MH, Reynolds CP, Houghton PJ, Alexander D, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Wozniak A, Smith MA: Initial testing (stage 1) of AT13387, an HSP90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:185-8, 2012
  2. Houghton PJ, Lock R, Carol H, Morton CL, Gorlick R, Anders Kolb E, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups CA, Zhang MX, Madden SL, Teicher BA, Smith MA: Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:200-9, 2012
  3. Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA, Houghton PJ, Smith MA. Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:916-23, 2012
  4. Houghton PJ, Kang MH, Reynolds CP, Morton CL, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Maris JM, Billups CA, Smith MA: Initial testing (Stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program. Pediatr Blood Cancer. 58:636-9, 2012
  5. Smith MA, Gorlick R, Kolb EA, Lock R, Carol H, Maris JM, Keir ST, Morton CL, Reynolds CP, Kang MH, Arts J, Bashir T, Janicot M, Kurmasheva RT, Houghton PJ: Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59: 329-32, 2012
  6. Gorlick R, Maris JM, Houghton PJ, Lock R, Carol H, Kurmasheva RT, Kolb EA, Keir ST, Reynolds CP, Kang MH, Billups CA, Smith MA: Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:518-24, 2012. PMID: 22102563
  7. Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:749-52, 2012. PMID: 22052829
  8. Kolb EA, Gorlick R, Keir ST, Maris JM, Lock R, Carol H, Kurmasheva RT, Reynolds CP, Kang MH, Wu J, Houghton PJ, Smith MA: Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatr Blood Cancer. 58:815-8, 2012. PMID 22052798
  9. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, Houghton PJ: Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:246-53, 2012. PMID: 22012946
  10. Xu J, Erdreich-Epstein A, Gonzalez-Gomez I, Melendez EY, Smbatyan G, Moats RA, Rosol M, Biegel J, Reynolds CP: Novel cell lines accurately reflect pediatric brain tumors. J Neurooncology 107:269-80, 2012. PMID: 22120608
  11. Gorlick R, Kolb EA, Houghton PJ, Morton CL, Neale G, Keir ST, Carol H, Lock R, Phelps D, Kang MH, Reynolds CP, Maris JM, Billups C, Smith MA: Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program. Pediatr Blood Cancer. 59:1266-74, 2012. PMID: 22315240
  12. Smith MA, Kang MH, Reynolds CP, Kurmasheva RT, Alexander D, Billups CA, Toretsky JA, Houghton PJ: Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma. Pediatr Blood Cancer. 59:753-5, 2012. PMID: 22315235
  13. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, Collins MH, Tagge E, Adkins S, Reynolds CP, Murray K, Lavey RS, Matthay KK, Castleberry R, Maris JM, Cohn SL: Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: Results of Children's Oncology Group study P9641. J Clin Oncol. 30:1842-8, 2012. PMID: 22529259
  14. Szymanska B, Wilczynska-Kalak U, Kang MH, Liem NL, Carol H, Boehm I, Groepper D, Reynolds CP, Stewart CF, Lock RB: Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts. PLoS One. 7:e33894, 2012. PMID: 22479469
  15. Goldsmith KC, Gross M, Peirce S, Luyindula D, Liu X, Vu A, Sliozberg M, Guo R, Zhao H, Reynolds CP, Hogarty MD: Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma. Cancer Res. 72:2565-2577, 2012.
  16. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB: Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:633-41, 2012. PMID: 22753001

2013

  1. Reynolds CP, Kang MH, Carol H, Lock R, Gorlick R, Kolb EA, Kurmasheva RT, Keir ST, Maris JM, Billups CA, Houghton PJ, Smith MA: Initial testing (stage 1) of the phosphatidylinositol 3' kinase Inhibitor, SAR245408 (XL147) by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 60:791-798, 2013.
  2. Shibina A, Seidel D, Somanchi S, Lode HN, Lee DA, Reynolds CP, Huebener N: Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity. J Mol Med 91:459-472, 2013.
  3. Sausen M, Leary RJ, Wu J, Reynolds CP, Liu X, Maris J, Blackford A, Parmigiani G, Diaz LA, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Hogarty MD: Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics 45:12-17, 2013.
  4. Keir ST, Maris JM, Reynolds CP, Kang MH, Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Wu J, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:783-90, 2013. PMID: 23335050
  5. Wood AC, Maris JM, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Wu J, Kurmasheva RT, Whiteman K, Houghton PJ, Smith MA. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:1860-7, 2013. PMID: 23798344
  6. Lock RB, Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. : Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 60:E42-5, 2013. PMID: 23303741
  7. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 60:1325-32, 2013. PMID 23553917
  8. Maurer BJ, Kang MH, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Villablanca JG, Czarnecki S, Beth Hasenauer B, Reynolds CP, Marachelian A: Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed neuroblastoma: A report from the NANT consortium. Pediatr Blood Cancer 60:1801-8, 2013. PMID: 23813912
  9. Kreissman SG, Seeger RC, Matthay KK, London WB, Sposto R, Grupp SA, Haas-Kogan DA, M.D., LaQuaglia MP, Yu AL, M.D., Diller L, Buxton A, Park JP, Cohn SL, Maris JM, Reynolds CP, Villablanca JG: Purged versus non-purged peripheral blood stem cell transplant for neuroblastoma. Lancet Oncology 14:999-1008, 2013. PMID: 23890779
  10. May WA, Grigoryan RS, Keshelava N, Cabral JD, Christensen LL, Jenabi J, Ji L, Lawlor ER, Reynolds CP: Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines. PLOS One Dec 2;8(12):e80060. doi: 10.1371/journal.pone.0080060, 2013. PMID: 24312454
  11. Kurmasheva RT, Reynolds CP, Kang MH, Allievi C, Houghton PJ, Smith MA: Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 Oct 26. doi: 10.1002/pbc.24800. [Epub ahead of print] PMID: 24166988
  12. Carol H, Gorlick R, Kolb EA, Morton CL, Manesh DM, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak A, Hickson I, Lyalin D, Kurmasheva RT, Houghton PJ, Smith MA, Lock R: Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2013 Sep 4. doi: 10.1002/pbc.24724. [Epub ahead of print] PMID: 24038993

2014

  1. Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA: Initial testing (stage 1) of the polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 61:158-64, 2014. PMID: 23956067
  2. Shah ED, Fisch BMA, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP: DrugPath: A database for academic investigators to match oncology molecular targets with drugs in development. Cancer Chemotherapy & Pharmacology Epub ahead of print Mar 25, 2014. PMID:24663501
  3. Carol H, Maris JM, Kang MH, Reynolds CP, Kolb EA, Gorlick R, Keir ST, Wu J, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB: Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Mar 24. doi: 10.1002/pbc.25026. [Epub ahead of print]. PMID 24664981
  4. MH Kang, CP Reynolds, JM Maris, R Gorlick, EA Kolb, R Lock, H Carol, ST Keir, J Wu, D Lyalin, RT Kurmasheva, PJ Houghton, MA Smith. Initial Testing (Stage 1) of the mTOR Kinase Inhibitor MLN0128 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer doi: 10.1002/pbc.24989. [Epub ahead of print] 2014 PMID: 24623675
  5. Ryu Y, Hall CP, Reynolds CP, MH Kang: Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human ALL cell line. (Provisionally accepted in Exp Biol Med)